Valerio Therapeutics
C4X
Company Profile
Business description
Valerio Therapeutics is a clinical-stage biotechnology company developing drug candidates using three proprietary platforms: the PlatON platform, DecoyTAC, and the V-Body platform, generating single-domain therapeutic antibodies. The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners. Its pipeline includes Metabolic Diseases, Immunology & Inflammatory.
Contact
49, Boulevard du General
Martial Valin
Paris75015
FRAT: +33 145587600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
25
Stocks News & Analysis
stocks
ASX gold miner overvalued despite stronger gold prices
Higher gold prices boosted profit yet shares remain materially overvalued.
stocks
ASX energy giant undervalued despite commissioning challenges
Near-term hurdles, long-term upside.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,198.80 | 29.80 | 0.33% |
| CAC 40 | 8,458.78 | 52.72 | 0.63% |
| DAX 40 | 25,464.01 | 102.98 | 0.41% |
| Dow JONES (US) | 52,747.32 | 537.24 | 1.03% |
| FTSE 100 | 10,871.02 | 89.27 | 0.83% |
| HKSE | 25,657.66 | 346.81 | 1.37% |
| NASDAQ | 24,876.91 | 55.17 | -0.22% |
| Nikkei 225 | 60,741.93 | 1,622.99 | -2.60% |
| NZX 50 Index | 13,965.75 | 103.82 | 0.75% |
| S&P 500 | 7,428.78 | 15.60 | 0.21% |
| S&P/ASX 200 | 9,037.10 | 33.60 | 0.37% |
| SSE Composite Index | 3,793.18 | 20.13 | -0.53% |